Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Manuel Hidalgo Medina acquired 3,562.341 deferred share units of Bristol-Myers Squibb on February 1, 2025.

Summary

• On February 1, 2025, Manuel Hidalgo Medina, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units.
• These units will convert into shares of common stock upon settlement, which occurs when Medina ceases to be a director or at a previously specified future date.
• The acquisition price was $58.95 per unit.
• Following the transaction, Medina beneficially owns 17,835.638 deferred share units, including deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company through deferred compensation.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing reflects routine executive compensation practices within publicly traded companies, where deferred share units are used as a form of long-term incentive.

Stakeholder Impact

• The acquisition of deferred share units by a director signals confidence in the company's future performance, which can positively influence shareholder sentiment.

Key Dates

Keywords

Deferred Share Units, Director, Form 4, BMY, Bristol-Myers Squibb, Acquisition